Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 11 January 2017 | By Zachary Brennan
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) on Wednesday released its agenda of new and revised draft guidance documents to be published this calendar year, and it includes several eagerly-awaited documents, such as ones on biosimilar interchangeability (which has been on the list since 2015) and a revision of a draft on postmarket safety reporting for drugs and biologics.
The 102 draft guidance documents slated for release in 2017 are on par with the number expected in 2016 (also 102 draft documents), but up significantly from the 60 guidance documents from 2013 and about 70 from 2014, and as in previous years, the largest chunk of new draft guidances will be procedural.
CDER plans to release 28 procedural draft guidelines in 2017, including ones on refuse to file issues with new drug application and biologics license applications, as well as several related to Risk Evaluation and Mitigation Strategies.
On the quality/chemistry manufacturing and controls (CMC) front, new drafts are expected on CMC postapproval manufacturing changes for specified biologics in annual reports, visual inspection of injectable drugs and in-vitro methods for the evaluation of abuse-deterrent properties of opioids.
As far as drafts that will be revised in 2017, FDA points to 27 documents (up from 21 revisions planned for 2016), including nine that were included on both the 2016 and 2017 lists, including:
Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2017
Tags: interchangeability, FDA guidance, guidance agenda, CDER guidance